December 20, 2017New England Journal of Medicine3,342 citationsOpen Access
View Full PaperTumor Mutational Burden and Response Rate to PD-1 Inhibition
Key Points
Key points are not available for this paper at this time.
Abstract
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.